Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519097826> ?p ?o ?g. }
- W2519097826 endingPage "159" @default.
- W2519097826 startingPage "146" @default.
- W2519097826 abstract "Summary A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 20%), would offer a new option for antibody replacement therapy in patients with primary immunodeficiency diseases (PIDD). The efficacy, safety, tolerability and pharmacokinetics of IGSC 20% were evaluated in a prospective trial in Europe in 49 patients with PIDD aged 2–67 years. Over a median of 358 days, patients received 2349 IGSC 20% infusions at monthly doses equivalent to those administered for previous intravenous or subcutaneous IgG treatment. The rate of validated acute bacterial infections (VASBIs) was significantly lower than 1 per year (0·022/patient-year, P < 0·0001); the rate of all infections was 4·38/patient-year. Median trough IgG concentrations were ≥ 8 g/l. There was no serious adverse event (AE) deemed related to IGSC 20% treatment; related non-serious AEs occurred at a rate of 0·101 event/infusion. The incidence of local related AEs was 0·069 event/infusion (0·036 event/infusion, when excluding a 13-year-old patient who reported 79 of 162 total related local AEs). The incidence of related systemic AEs was 0·032 event/infusion. Most related AEs were mild, none were severe. For 64·6% of patients and in 94·8% of IGSC 20% infusions, no local related AE occurred. The median infusion duration was 0·95 (range = 0·3-4·1) h using mainly one to two administration sites [median = 2 sites (range = 1–5)]. Almost all infusions (99·8%) were administered without interruption/stopping or rate reduction. These results demonstrate that IGSC 20% provides an effective and well-tolerated therapy for patients previously on intravenous or subcutaneous treatment, without the need for dose adjustment." @default.
- W2519097826 created "2016-09-23" @default.
- W2519097826 creator A5005453736 @default.
- W2519097826 creator A5009789236 @default.
- W2519097826 creator A5016649272 @default.
- W2519097826 creator A5033886272 @default.
- W2519097826 creator A5041776876 @default.
- W2519097826 creator A5050816060 @default.
- W2519097826 creator A5058777943 @default.
- W2519097826 creator A5060535400 @default.
- W2519097826 creator A5070985333 @default.
- W2519097826 creator A5079719869 @default.
- W2519097826 creator A5083214655 @default.
- W2519097826 creator A5083846868 @default.
- W2519097826 date "2016-10-18" @default.
- W2519097826 modified "2023-10-18" @default.
- W2519097826 title "Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies" @default.
- W2519097826 cites W1931185549 @default.
- W2519097826 cites W1978261191 @default.
- W2519097826 cites W1982773941 @default.
- W2519097826 cites W1984123981 @default.
- W2519097826 cites W1991607908 @default.
- W2519097826 cites W1994238113 @default.
- W2519097826 cites W1996732435 @default.
- W2519097826 cites W2006703104 @default.
- W2519097826 cites W2021597023 @default.
- W2519097826 cites W2035488076 @default.
- W2519097826 cites W2036304065 @default.
- W2519097826 cites W2037377025 @default.
- W2519097826 cites W2037581442 @default.
- W2519097826 cites W2045096978 @default.
- W2519097826 cites W2049769828 @default.
- W2519097826 cites W2058731890 @default.
- W2519097826 cites W2059451555 @default.
- W2519097826 cites W2060945534 @default.
- W2519097826 cites W2061423696 @default.
- W2519097826 cites W2065352039 @default.
- W2519097826 cites W2082066722 @default.
- W2519097826 cites W2091357222 @default.
- W2519097826 cites W2096782143 @default.
- W2519097826 cites W2111354448 @default.
- W2519097826 cites W2114152260 @default.
- W2519097826 cites W2133739445 @default.
- W2519097826 cites W2134678353 @default.
- W2519097826 cites W2156046580 @default.
- W2519097826 cites W2165561908 @default.
- W2519097826 cites W2168448906 @default.
- W2519097826 cites W2279672260 @default.
- W2519097826 cites W2330505390 @default.
- W2519097826 cites W2411021627 @default.
- W2519097826 cites W2572233504 @default.
- W2519097826 cites W4292806894 @default.
- W2519097826 doi "https://doi.org/10.1111/cei.12866" @default.
- W2519097826 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5167020" @default.
- W2519097826 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27613250" @default.
- W2519097826 hasPublicationYear "2016" @default.
- W2519097826 type Work @default.
- W2519097826 sameAs 2519097826 @default.
- W2519097826 citedByCount "35" @default.
- W2519097826 countsByYear W25190978262017 @default.
- W2519097826 countsByYear W25190978262018 @default.
- W2519097826 countsByYear W25190978262019 @default.
- W2519097826 countsByYear W25190978262020 @default.
- W2519097826 countsByYear W25190978262021 @default.
- W2519097826 countsByYear W25190978262022 @default.
- W2519097826 countsByYear W25190978262023 @default.
- W2519097826 crossrefType "journal-article" @default.
- W2519097826 hasAuthorship W2519097826A5005453736 @default.
- W2519097826 hasAuthorship W2519097826A5009789236 @default.
- W2519097826 hasAuthorship W2519097826A5016649272 @default.
- W2519097826 hasAuthorship W2519097826A5033886272 @default.
- W2519097826 hasAuthorship W2519097826A5041776876 @default.
- W2519097826 hasAuthorship W2519097826A5050816060 @default.
- W2519097826 hasAuthorship W2519097826A5058777943 @default.
- W2519097826 hasAuthorship W2519097826A5060535400 @default.
- W2519097826 hasAuthorship W2519097826A5070985333 @default.
- W2519097826 hasAuthorship W2519097826A5079719869 @default.
- W2519097826 hasAuthorship W2519097826A5083214655 @default.
- W2519097826 hasAuthorship W2519097826A5083846868 @default.
- W2519097826 hasBestOaLocation W25190978261 @default.
- W2519097826 hasConcept C112705442 @default.
- W2519097826 hasConcept C120665830 @default.
- W2519097826 hasConcept C121332964 @default.
- W2519097826 hasConcept C126322002 @default.
- W2519097826 hasConcept C159654299 @default.
- W2519097826 hasConcept C197934379 @default.
- W2519097826 hasConcept C203014093 @default.
- W2519097826 hasConcept C2778375690 @default.
- W2519097826 hasConcept C61511704 @default.
- W2519097826 hasConcept C71924100 @default.
- W2519097826 hasConcept C90924648 @default.
- W2519097826 hasConceptScore W2519097826C112705442 @default.
- W2519097826 hasConceptScore W2519097826C120665830 @default.
- W2519097826 hasConceptScore W2519097826C121332964 @default.
- W2519097826 hasConceptScore W2519097826C126322002 @default.
- W2519097826 hasConceptScore W2519097826C159654299 @default.
- W2519097826 hasConceptScore W2519097826C197934379 @default.
- W2519097826 hasConceptScore W2519097826C203014093 @default.